Authors' response to "Evaluation of Treatments for HIV-Associated Kaposi Sarcoma in Africa"

Affiliations

¹ Epicentre, 14-34 Avenue Jean Jaurès, 75019, Paris, France. matthew.coldiron@epicentre.msf.org.
² Médecins Sans Frontières, Maputo, Mozambique.
³ Ministry of Health, Maputo, Mozambique.
⁴ Médecins Sans Frontières, Geneva, Switzerland.
⁵ University Hospitals of Geneva, Geneva, Switzerland.

Matthew E Coldiron et al. Infect Agent Cancer. 2021.

. 2021 May 5;16(1):27.

doi: 10.1186/s13027-021-00372-5.

¹ Epicentre, 14-34 Avenue Jean Jaurès, 75019, Paris, France. matthew.coldiron@epicentre.msf.org.
² Médecins Sans Frontières, Maputo, Mozambique.
³ Ministry of Health, Maputo, Mozambique.
⁴ Médecins Sans Frontières, Geneva, Switzerland.
⁵ University Hospitals of Geneva, Geneva, Switzerland.

No abstract available

Keywords: AIDS-related opportunistic infections; Acquired Immunodeficiency Syndrome; Doxorubicin; Kaposi sarcoma; Mozambique.

Conflict of interest statement

The authors declare that they have no competing interests.

1. Coldiron ME, Gutierrez Zamudio AG, Manuel R, Luciano G, Rusch B, Ciglenecki I, et al. Outcomes of AIDS-associated Kaposi sarcoma in Mozambique after treatment with pegylated liposomal doxorubicin. Infect Agent Cancer. 2021;16:2 - PMC - PubMed
1. Krown SE, Moser CB, Macphail P, Matining RM, Godfrey C, Caruso SR, et al. Treatment of advanced AIDS-associated Kaposi sarcoma in resource-limited settings: a three-arm, open-label, randomised, non-inferiority trial. Lancet. 2020;395:1195–207. doi: 10.1016/S0140-6736(19)33222-2. - DOI - PMC - PubMed
1. Fardhdiani V, Molfino L, Zamudio AG, Manuel R, Luciano G, Ciglenecki I, et al. HIV-associated Kaposi’s sarcoma in Maputo, Mozambique: Outcomes in a specialized treatment center, 2010–2015. Infect Agent Cancer. 2018;13:5. - PMC - PubMed